NDA 021135 · Am Regent
Venofer
Iron Sucrose · Intravenous · Parenteral Iron Replacement
Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Nov 6, 2000
Approved uses
5
Original approval plus efficacy supplements
Registered trials
125
33 Phase 3, 7 recruiting
FAERS reports
9,664
7,633 serious, 935 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 1, 2026.
Venofer is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). Venofer is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). ( 1 )
Mechanism: Venofer is an aqueous complex of poly-nuclear iron (III)-hydroxide in sucrose. Following intravenous administration, Venofer is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron in the precursor cells is incorporated into hemoglobin as the cells mature into red blood cells.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 21, 2012 Supplement 24 · Efficacy Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
- Oct 17, 2005 Supplement 13 · Efficacy LabelLetter
- Jun 17, 2005 Supplement 8 · Efficacy ReviewLabelLetter
- Jun 2, 2003 Supplement 6 · Efficacy Letter
- Nov 6, 2000 Original approval · Type 3 - New Dosage Form LabelLetterReview
5 products under this application
- VENOFER · IRON SUCROSE EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML) · INJECTABLE, INTRAVENOUS · Discontinued
- VENOFER · IRON SUCROSE EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML) · INJECTABLE, INTRAVENOUS · Discontinued
- VENOFER · IRON SUCROSE EQ 100MG IRON/5ML (EQ 20MG IRON/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AB
- VENOFER · IRON SUCROSE EQ 200MG IRON/10ML (EQ 20MG IRON/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AB
- VENOFER · IRON SUCROSE EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Iron Sucrose" as an intervention, any sponsor and status, largest first.
- Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal FunctionPivotal-lookingCompleted
American Regent, Inc.Industry
NCT00981045 · 2,561 participants · Start Aug 2009 · Primary completion Jul 2011
Drug: Ferric Carboxymaltose (FCM); Iron Sucrose (Venofer) · For: Iron Deficiency Anemia; Impaired Renal Function
Sites: Norristown, Pennsylvania
- Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney DiseasePivotal-lookingCompleted
Pharmacosmos A/SIndustry
NCT02940860 · 1,538 participants · Start Nov 29, 2016 · Primary completion May 29, 2018
Drug: Iron isomaltoside/ferric derisomaltose; Iron sucrose · For: Iron Deficiency Anaemia; Iron Deficiency Anemia; Chronic Kidney Disease
Sites: Huntsville, Alabama; Little Rock, Arkansas; Chula Vista, California · 141 sites in all
- Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)Pivotal-lookingCompleted
Pharmacosmos A/SIndustry
NCT02940886 · 1,512 participants · Start Nov 8, 2016 · Primary completion Mar 28, 2018
Drug: Iron isomaltoside/ferric derisomaltose; Iron sucrose · For: Iron Deficiency Anaemia; Iron Deficiency Anemia
Sites: Birmingham, Alabama; Dothan, Alabama; Guntersville, Alabama · 114 sites in all
- Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency AnemiaPivotal-lookingCompleted
American Regent, Inc.Industry
NCT00704353 · 735 participants · Start Jun 2008 · Primary completion Jul 2009
Drug: Ferric Carboxymaltose; Standard Medical Care (SMC) · For: Anemia
Sites: Norristown, Pennsylvania
- A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency AnemiaPivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT01114204 · 605 participants · Start Aug 10, 2010 · Primary completion Nov 9, 2011
Drug: Ferumoxytol; Iron Sucrose · For: Iron Deficiency Anemia
Sites: Adelaide, Australia; Ballarat, Australia; Concord, Australia · 96 sites in all
- Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency AnemiaPivotal-lookingCompleted
Arrowhead Regional Medical CenterAcademic, hospital or other
NCT06366698 · 518 participants · Start Nov 21, 2023 · Primary completion Sep 12, 2025
Drug: Venofer 200 MG Per 10 ML Injection; Ferrous sulfate · For: Iron Deficiency Anemia of Pregnancy
Sites: Colton, California
- IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron SucrosePivotal-lookingCompleted
Pharmacosmos A/SIndustry
NCT02130063 · 511 participants · Start May 2014 · Primary completion Aug 2015
Drug: iron isomaltoside 1000 (Monofer®); iron sucrose (Venofer®) · For: Iron Deficiency Anaemia
Sites: Wilmington, Delaware
- Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00661999 · 502 participants · Start Jan 2006 · Primary completion Mar 2009
Drug: darbepoetin alfa; sodium ferric gluconate complex in sucrose · For: Anemia; Leukemia; Lymphoma and 4 more
Sites: Scottsdale, Arizona; Rochester, Minnesota
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity1,169
- nausea1,035
- dyspnoea1,014
- off label use654
- pruritus651
- vomiting647
- diarrhoea554
- rash550
- hypotension530
- dizziness520
- urticaria495
- headache473
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 48 |
| 2005 | 68 |
| 2006 | 86 |
| 2007 | 141 |
| 2008 | 157 |
| 2009 | 270 |
| 2010 | 240 |
| 2011 | 190 |
| 2012 | 269 |
| 2013 | 299 |
| 2014 | 277 |
| 2015 | 384 |
| 2016 | 444 |
| 2017 | 420 |
| 2018 | 485 |
| 2019 | 843 |
| 2020 | 589 |
| 2021 | 690 |
| 2022 | 904 |
| 2023 | 814 |
| 2024 | 716 |
| 2025 | 704 |
| 2026 | 626 |
Recalls
3 FDA enforcement reports for this application.
Nov 11, 2024 · Class II · Ongoing
Presence of Particulate Matter: Potential for glass delamination from the vials.
Nov 11, 2024 · Class II · Ongoing
Presence of Particulate Matter: Potential for glass delamination from the vials.
Nov 11, 2024 · Class II · Ongoing
Presence of Particulate Matter: Potential for glass delamination from the vials.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Venofer (Iron Sucrose Complex)
2024 spending
$22K
Beneficiaries
44
80 claims
Per beneficiary
$504
$11.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $5,736 |
| 2023 | $0 |
| 2024 | $22,188 |
Part B: Venofer (Iron Sucrose Complex) · HCPCS J1756
2024 spending
$3.0M
Beneficiaries
15,093
64,302 claims
Per beneficiary
$200
2024 ASP limit $0.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,411,573 |
| 2021 | $2,713,532 |
| 2022 | $3,100,943 |
| 2023 | $3,631,028 |
| 2024 | $3,011,707 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.
Macdougall IC, White C, Anker SD, et al. · N Engl J Med 2019 · Equivalence Trial, Multicenter Study
- Effect and safety of intravenous iron compared to oral iron for treatment of iron deficiency anaemia in pregnancy.
Nicholson L, Axon E, Daru J, et al. · Cochrane Database Syst Rev 2024 · Systematic Review
- Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis.
Rogoziska E, Daru J, Nicolaides M, et al. · Lancet Haematol 2021 · Systematic Review, Network Meta-Analysis
- Systematic review and meta-analysis of intravenous iron-carbohydrate complexes in HFrEF patients with iron deficiency.
Sindone A, Doehner W, Comin-Colet J · ESC Heart Fail 2023 · Meta-Analysis, Systematic Review
- Clinical effectiveness of ferric carboxymaltose (iv) versus iron sucrose (iv) in treatment of iron deficiency anaemia in pregnancy: A systematic review and meta-analysis.
Srimathi G, Revathy R, Bagepally BS, et al. · Indian J Med Res 2024 · Meta-Analysis, Systematic Review
- Efficacy, Safety, and Tolerability of Ferric Carboxymaltose and Iron Sucrose in Iron-Deficiency Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Tanrverdi LH, Sarc A · Turk J Haematol 2025 · Systematic Review, Meta-Analysis
Sponsor: Am Regent
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.